Loading stock data…
ATHE
$4.72+0.18 (+4.07%)
Market ClosedLast close May 1
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alterity Therapeutics Limited in the Healthcare sector is trading at $4.72. The stock is currently 33% below its 52-week high of $7.00, remaining 17.2% above its 200-day moving average. Technical signals show neutral RSI of 69 and bullish MACD crossover, explaining why ATHE maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Overbought levels (RSI 69) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.72
Potential Upside
5%
Whystock Fair Value$4.96
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Buy
Mean target$12.00+154.0%
Range$12.00 – $12.00
Fundamentals
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$85.85M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.07
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-22.38%
Volume
Today's trading volume
39,571
Recent News
Alterity Therapeutics Limited's (ASX:ATH) Path To Profitability
With the business potentially at an important milestone, we thought we'd take a closer look at Alterity Therapeutics...
Alterity Says Data Showed Potential Multiple System Atrophy Drug Slowed Disease Progression in Phase 2 Study
Alterity Therapeutics (ATHE) said Thursday that data from a 77-patient phase 2 clinical trial of its
Alterity Therapeutics (ATHE) Presents Positive Phase 2 Data for ATH434
Alterity Therapeutics Limited (NASDAQ:ATHE) is one of the best performing ASX stocks in 2025. On September 15, the company shared data from its Phase 2 clinical trial of the drug ATH434-201 at the American Neurological Association Annual Meeting in Baltimore. The clinical trial involved people with Multiple System Atrophy (MSA), a rare brain condition that […]
We Think Alterity Therapeutics (ASX:ATH) Can Easily Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, Alterity...
Alterity Therapeutics Limited (ATHE) Announces Positive Topline Data From Phase 2 Trial of ATH434 in Multiple System Atrophy
Alterity Therapeutics Limited (NASDAQ:ATHE) is among the 12 Best Australian Stocks to Buy Right Now. The company recently reported positive topline data from an open-label Phase 2 clinical trial of ATH434-202 in individuals with multiple system atrophy (MSA). The trial involved evaluating patients with more advanced disease than studied earlier in the double-blind Phase 2 […]